

Peter D Cole

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4083719/publications.pdf>

Version: 2024-02-01

74
papers

1,677
citations

304743

22
h-index

302126

39
g-index

77
all docs

77
docs citations

77
times ranked

2312
citing authors

#	ARTICLE	IF	CITATIONS
1	Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 890-900.	0.8	3
2	Cognitive impairment persists at least 1 year after juvenile rats are treated with methotrexate. <i>Neuropharmacology</i> , 2022, 206, 108939.	4.1	5
3	Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001. <i>Blood Advances</i> , 2022, 6, 1329-1341.	5.2	30
4	Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29581.	1.5	6
5	Durable remission for four pediatric patients with high-risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2022, , e29649.	1.5	1
6	Provider and staff crisis well-being associated with trust in leadership and baseline burnout. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29497.	1.5	2
7	Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28719.	1.5	26
8	LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 606-613.	1.3	13
9	Associations between race and survival in pediatric patients with diffuse large B-cell lymphoma. <i>Cancer Medicine</i> , 2021, 10, 1327-1334.	2.8	2
10	Genetic ancestry and skeletal toxicities among childhood acute lymphoblastic leukemia patients in the DFCI 05-001 cohort. <i>Blood Advances</i> , 2021, 5, 451-458.	5.2	5
11	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Cancer Discovery</i> , 2021, 11, 1424-1439.	9.4	16
12	Severe Vincristine-related Neurotoxicity in 5 Patients With Pediatric Acute Lymphoblastic Leukemia Requiring Discontinuation of Vincristine. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, Publish Ahead of Print, e997-e999.	0.6	2
13	Biomarkers of Cognitive Impairment in Pediatric Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2021, 39, 1766-1774.	1.6	7
14	Well-Being of Pediatric Hematology Oncology Providers and Staff During the COVID-19 Pandemic in the New York and New Jersey Epicenter. <i>JCO Oncology Practice</i> , 2021, 17, e925-e935.	2.9	11
15	Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. <i>Journal of Clinical Oncology</i> , 2021, 39, 3496-3505.	1.6	36
16	Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data. <i>Blood</i> , 2021, 138, 879-879.	1.4	3
17	Impact of Age, Body Surface Area, and Body Mass Index on Pegaspargase Toxicity and Pharmacokinetics: A Report from the DFCI ALL Consortium. <i>Blood</i> , 2021, 138, 3396-3396.	1.4	1
18	Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001. <i>Blood</i> , 2021, 138, 3485-3485.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Pediatric hodgkin lymphoma: disparities in survival by race. <i>Leukemia and Lymphoma</i> , 2020, 61, 546-556.	1.3	7
20	Safety of limited therapeutic monitoring after high-dose methotrexate in developing countries. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28540.	1.5	2
21	<i>Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001</i>. <i>Blood</i> , 2020, 136, 30-31.	1.4	3
22	Frequency and Prognostic Significance of Recurrent Gene Mutations in Pediatric B-ALL: Report from the DFCI ALL Consortium. <i>Blood</i> , 2020, 136, 15-16.	1.4	1
23	Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. <i>British Journal of Haematology</i> , 2019, 187, 39-48.	2.5	44
24	Childhood leukemia survivors exhibit deficiencies in sensory and cognitive processes, as reflected by event-related brain potentials after completion of curative chemotherapy: A preliminary investigation. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2019, 41, 814-831.	1.3	8
25	Fluctuations in dietary intake during treatment for childhood leukemia: A report from the DALLT cohort. <i>Clinical Nutrition</i> , 2019, 38, 2866-2874.	5.0	14
26	Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia/lymphoma: Results of DFCI 11-001.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10006-10006.	1.6	7
27	Reply to comment on: Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27082.	1.5	0
28	An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26871.	1.5	23
29	Liposomal Cytarabine Induces Less Neurocognitive Dysfunction Than Intrathecal Methotrexate in an Animal Model. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, e91-e96.	0.6	4
30	Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. <i>Blood Advances</i> , 2018, 2, 529-533.	5.2	34
31	Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. <i>Blood Advances</i> , 2018, 2, 1449-1458.	5.2	73
32	Methotrexate causes persistent deficits in memory and executive function in a juvenile animal model. <i>Neuropharmacology</i> , 2018, 139, 76-84.	4.1	30
33	Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1–2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1229-1238.	10.7	67
34	Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27256.	1.5	26
35	Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 927-927.	1.4	13
36	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Blood</i> , 2018, 132, 261-261.	1.4	3

#	ARTICLE	IF	CITATIONS
37	A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26393.	1.5	13
38	Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia. <i>Supportive Care in Cancer</i> , 2017, 25, 449-457.	2.2	21
39	Dietary intake and childhood leukemia: The Diet and Acute Lymphoblastic Leukemia Treatment (DALLT) cohort study. <i>Nutrition</i> , 2016, 32, 1103-1109.e1.	2.4	29
40	Long-term outcomes for children with acute lymphoblastic leukemia (ALL) treated on The Cancer Institute of New Jersey ALL trial (CINJALL). <i>Leukemia and Lymphoma</i> , 2016, 57, 2275-2280.	1.3	4
41	Asparaginase <i>Erwinia chrysanthemi</i> as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to <i>E. coli</i> -derived asparaginase. <i>Expert Review of Hematology</i> , 2016, 9, 227-234.	2.2	14
42	Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001. <i>Blood</i> , 2016, 128, 175-175.	1.4	11
43	Excellent Outcome of Children with Down Syndrome (DS) and Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 00-001 and 05-001. <i>Blood</i> , 2016, 128, 761-761.	1.4	0
44	Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium. <i>Blood</i> , 2016, 128, 1729-1729.	1.4	0
45	Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 2205-2211.	1.6	57
46	Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 971-983.	2.0	65
47	Intravenous pegylated asparaginase versus intramuscular native <i>Escherichia coli</i> l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1677-1690.	10.7	193
48	A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study. <i>British Journal of Haematology</i> , 2015, 170, 118-122.	2.5	22
49	Does genetic susceptibility increase risk for neurocognitive decline among patients with acute lymphoblastic leukemia?. <i>Future Oncology</i> , 2015, 11, 1855-1858.	2.4	1
50	Higher Incidence of Treatment-Related Toxicities in Non-Hispanic Patients Undergoing Therapy for Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001. <i>Blood</i> , 2015, 126, 248-248.	1.4	5
51	Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 249-249.	1.4	6
52	Homozygosity for the 2R Tandem Repeat Polymorphism in the Thymidylate Synthase (TS) Promoter Is Associated with Increased Risk for Bony Morbidity Among Children Treated for Acute Lymphoblastic Leukemia on DFCI Protocol 05-001. <i>Blood</i> , 2015, 126, 251-251.	1.4	3
53	<i>Ikaros</i> Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease. <i>Blood</i> , 2015, 126, 2613-2613.	1.4	4
54	Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group. <i>Blood</i> , 2015, 126, 3927-3927.	1.4	5

#	ARTICLE	IF	CITATIONS
55	Polymorphisms in Genes Related to Oxidative Stress Are Associated with Inferior Cognitive Function after Therapy for Childhood ALL. <i>Blood</i> , 2014, 124, 856-856.	1.4	1
56	Outcome of childhood T-cell acute lymphoblastic leukemia (T-ALL): Results from DFCI protocol 05-001.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10015-10015.	1.6	4
57	Dietary Intake of Zinc and Severity of Infection during Prophase/Induction in Children with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3659-3659.	1.4	0
58	Memantine Protects Rats Treated with Intrathecal Methotrexate from Developing Spatial Memory Deficits. <i>Clinical Cancer Research</i> , 2013, 19, 4446-4454.	7.0	38
59	Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 972-978.	1.5	56
60	Results Of The DFCI ALL Consortium Protocol 05-001 For Children and Adolescents With Newly Diagnosed ALL. <i>Blood</i> , 2013, 122, 838-838.	1.4	7
61	Variations in Energy and Nutrient Specific Consumption Over the Course of Therapy in Children with Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2012, 120, 2575-2575.	1.4	0
62	The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium. <i>European Journal of Cancer</i> , 2011, 47, 1373-1379.	2.8	99
63	Persistent cognitive deficits, induced by intrathecal methotrexate, are associated with elevated CSF concentrations of excitotoxic glutamate analogs and can be reversed by an NMDA antagonist. <i>Behavioural Brain Research</i> , 2011, 225, 491-497.	2.2	62
64	Randomized Comparison of IV PEG and IM E. Coli Asparaginase in Children and Adolescents with Acute Lymphoblastic Leukemia: Results of the DFCI ALL Consortium Protocol 05-01. <i>Blood</i> , 2011, 118, 874-874.	1.4	6
65	Systemic methotrexate induces spatial memory deficits and depletes cerebrospinal fluid folate in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 94, 454-463.	2.9	45
66	Intrathecal methotrexate induces focal cognitive deficits and increases cerebrospinal fluid homocysteine. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 95, 428-433.	2.9	43
67	EARLY [¹⁸ F]FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY-BASED RESPONSE EVALUATION AFTER TREATMENT WITH GEMCITABINE AND VINOURELBINE FOR REFRACTORY HODGKIN DISEASE: A CHILDREN'S ONCOLOGY GROUP REPORT. <i>Pediatric Hematology and Oncology</i> , 2010, 27, 650-657.	0.8	2
68	Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group Report. <i>Journal of Clinical Oncology</i> , 2009, 27, 1456-1461.	1.6	56
69	Folate Homeostasis in Cerebrospinal Fluid During Therapy for Acute Lymphoblastic Leukemia. <i>Pediatric Neurology</i> , 2009, 40, 34-41.	2.1	39
70	Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 65-75.	2.3	16
71	Pharmacodynamic properties of methotrexate and Aminotrexate™ during weekly therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 826-834.	2.3	29
72	Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia. <i>Mental Retardation and Developmental Disabilities Research Reviews</i> , 2006, 12, 174-183.	3.6	72

#	ARTICLE	IF	CITATIONS
73	DEXTROMETHORPHAN IS EFFECTIVE IN THE TREATMENT OF SUBACUTE METHOTREXATE NEUROTOXICITY. Pediatric Hematology and Oncology, 2002, 19, 319-327.	0.8	107
74	Benign outcome of RSV infection in children with cancer. Medical and Pediatric Oncology, 2001, 37, 24-29.	1.0	13